(S)-(+)-Ibuprofen - CAS 51146-56-6
Catalog number: 51146-56-6
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C13H18O2
Molecular Weight:
206.28
COA:
Inquire
Targets:
Cox-2 | COX
Description:
Be capable of inhibiting cyclooxygenase (COX) at clinically relevant concentrations; As an enantiomer of (R)-(-)-Ibuprofen, it more potently inhibits COX activity; A non-steroidal anti-inflammatory drug
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
Be capable of inhibiting cyclooxygenase (COX) at clinically relevant concentrations; As an enantiomer of (R)-(-)-Ibuprofen, it more potently inhibits COX activity; A non-steroidal anti-inflammatory drug
Appearance:
White to Off-White Solid
Synonyms:
(S)-Ibuprofen
Solubility:
100mMin DMSO;100mM in ethanol; dichloromethane, ethyl acetate, and methanol;
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
MSDS:
Inquire
Quality Standard:
In-house
Quantity:
Grams-Kilos
Melting Point:
45-47°C
InChIKey:
HEFNNWSXXWATRW-JTQLQIEISA-N
InChI:
1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)/t10-/m0/s1
Canonical SMILES:
CC(C)CC1=CC=C(C=C1)C(C)C(=O)O
1.Influence of temperature on toxicity of single pharmaceuticals and mixtures, in the crustacean A. desmarestii.
Nieto E1, Hampel M2, González-Ortegón E3, Drake P4, Blasco J4. J Hazard Mater. 2016 Mar 24;313:159-169. doi: 10.1016/j.jhazmat.2016.03.061. [Epub ahead of print]
Lethal and sublethal responses of the shrimp Atyaephyra desmarestii exposed to three pharmaceutical compounds, Diclofenac (DF), Ibuprofen (IB) and Carbamazepine (CBZ), individually and in mixtures, were evaluated under two temperature scenarios. LC50 (96h) values were obtained individually at 20° and 25°C. At 25°C, mortality in binary and ternary mixtures is higher than at 20°C. The toxicity of the mixtures was predicted on the basis of individual mortality data using two toxicity models: Concentration addition (CA) and Independent action (IA). Our results showed that neither CA nor IA unequivocally predicted the observed toxicity of binary and ternary mixtures. For sublethal toxicity, selected endpoints were: ingestion rate, osmoregulatory capacity and respiration rate. Regarding osmoregulatory capacity, no significant differences were found. The highest ingestion rates were recorded in organisms exposed at 25°C, irrespective of the compound, after 30 and 60min of exposure.
2.Active removal of ibuprofen by Money plant enhanced by ferrous ions.
Chehrenegar B1, Hu J2, Ong SL1. Chemosphere. 2016 Feb;144:91-6. doi: 10.1016/j.chemosphere.2015.08.060. Epub 2015 Sep 5.
In this study, the removal of ibuprofen (IBP), a pharmaceutical compound, from aqueous media by Money plant (Epipremnum aureum) was investigated. The effect of ferrous iron (Fe(2+)) on enhancing the IBP removal rate was also analyzed. The first-order removal rate constants showed higher values for lower IBP initial concentrations in the range of 0.20-0.28 d(-1) for an initial concentration of 125 μg L(-1) to 0.03-0.13 d(-1) for an initial concentration of 1000 μg L(-1). Introducing ferrous iron to the aqueous media enhanced the first-order removal rate constant up to 6.5 times in a 3 d time period. Along with the removal of IBP from the media, the endogenous concentration of H2O2 also decreased presumably by the production of hydroxyl radical (·OH). Reduction in the endogenous H2O2 concentration was recorded to be 38% and 98% in the absence and presence of Fe(2+) respectively in the first day and the H2O2 level remained considerably low until day 7 which then gradually increased slightly.
3.Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys.
Pelletier JP1, Martel-Pelletier J2, Rannou F3, Cooper C4. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S22-7. doi: 10.1016/j.semarthrit.2015.11.009. Epub 2015 Dec 2.
Non-steroidal anti-inflammatory drugs (NSAIDs) are at the cornerstone of treatment for osteoarthritis (OA). In recent years, the widespread use of oral NSAIDs has been called into question due to the appearance of significant upper gastrointestinal (GI) complications and cardiovascular (CV) adverse events (AEs). However, NSAIDs are non-homogeneous, and there are noticeable differences between them in AE risk for GI and CV events. Nevertheless, if properly prescribed oral NSAIDs can provide an effective and safe treatment for OA in real-life situations. The identification of patients with significant CV and/or GI risk is critical, and the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) treatment algorithm provides guidance on appropriate treatments for OA patients with elevated risk. Among non-selective NSAIDs, ibuprofen and naproxen seem preferable to diclofenac, the latter being associated with higher CV risk.
4.Cysteine amide adduct formation from carboxylic acid drugs via UGT-mediated bioactivation in human liver microsomes.
Harada H, Toyoda Y, Endo T, Kobayashi M. Pharmazie. 2015 Oct;70(10):678-83.
Although chemical trapping has been widely used to evaluate cytochrome P450-mediated drug bioactivation, thus far, only a few in vitro-trapping studies have been performed on UDP-glucuronosyltransferase (UGT)-mediated drug bioactivation. In this study, we used cysteine (Cys) as trapping agent to gain new insights into the UGT-mediated bioactivation involving acyl glucuronides of carboxylic acid drugs. Diclofenac, ketoprofen and ibuprofen were incubated in human liver microsomes with UDPGA and Cys, followed by analysis using ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS). The N-acyl-Cys amide adduct of diclofenac was characterized by mass analysis and was detectable even in photodiode array analysis. Our data indicated that the formation of such adducts reflects the reactivity of the corresponding acyl glucuronides. In addition, it was suggested that the adduct formation requires an N-terminal Cys moiety with both a free amine and a free thiol group, from the results using various cysteine derivatives.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Cox-2 Products


CAS 2438-72-4 Bufexamac

Bufexamac
(CAS: 2438-72-4)

Bufexamac is a COX inhibitor for IFN-α release with EC50 of 8.9 μM.Bufexamac is a drug used as an anti-inflammatory agent on the skin, as well as rectally. Comm...

CAS 13710-19-5 Tolfenamic Acid

Tolfenamic Acid
(CAS: 13710-19-5)

A COX-2 inhibitor with IC50 of 0.2 μM

CAS 1262956-64-8 NCX 466

NCX 466
(CAS: 1262956-64-8)

NCX 466 is a cyclooxygenase inhibiting nitric oxide donors (CINODs). NCX 466 shows higher efficacy in reducing levels of profibrotic cytokine transforming growt...

CAS 198470-85-8 Parecoxib Sodium

Parecoxib Sodium
(CAS: 198470-85-8)

The prodrug Parecoxib as well as its active metabolite val have a specific affinity to the cannabinoid (CB) receptor measured in CB1-expressing HEK 293 cells an...

CAS 141505-32-0 Ibuprofen lysinate

Ibuprofen lysinate
(CAS: 141505-32-0)

Dexibuprofen is a Cyclooxygenase inhibitor originated by Gebro Pharma GmbH. It is a non-steroidal anti-inflammatory drug as the active dextrorotatory enantiomer...

CAS 116686-15-8 FK 3311

FK 3311
(CAS: 116686-15-8)

A selective COX-2 inhibitor

CAS 287118-97-2 NCX 4040

NCX 4040
(CAS: 287118-97-2)

NCX 4040 is a NO-donating aspirin with anti-inflammatory activity. It can decrease COX-2 expression with IC50 value of 0.13 μM. It can also disrupt proteasome-m...

CAS 162011-90-7 Rofecoxib

Rofecoxib
(CAS: 162011-90-7)

A COX-2 inhibitor( IC50s = 26 nM and > 50 µM in human osteosarcoma cells )

CAS 31842-01-0 Indoprofen

Indoprofen
(CAS: 31842-01-0)

Indoprofen, a non-steroidal anti-inflammatory drug, is a cyclooxygenase inhibitor and used for the treatment of pain and inflammation and spinal muscular atroph...

CAS 53164-05-9 Acemetacin

Acemetacin
(CAS: 53164-05-9)

COX inhibitor; A non-steroidal anti-inflammatory drug

CAS 189954-96-9 Firocoxib

Firocoxib
(CAS: 189954-96-9)

A selective COX-2 inhibitor

O-Acetyl Salicylhydroxamic Acid
(CAS: 199854-00-7)

An irreversible, non-selective inhibitor of COX-1 and COX-2

CAS 443919-96-8 CAY10416

CAY10416
(CAS: 443919-96-8)

A dual COX-2/5-LO inhibitor

CAS 41340-25-4 Etodolac

Etodolac
(CAS: 41340-25-4)

A non-selective inhibitor of COX

CAS 23513-14-6 Gingerol

Gingerol
(CAS: 23513-14-6)

Gingerol is the active constituent of fresh ginger. It is bioactive compound found in ginger (Zingiber officinale) with antioxidant activity, which functions as...

CAS 202409-33-4 Etoricoxib

Etoricoxib
(CAS: 202409-33-4)

A selective COX-2 inhibitor

CAS 169590-42-5 Celecoxib

Celecoxib
(CAS: 169590-42-5)

A highly selective COX-2 inhibitor

CAS 99464-64-9 Ampiroxicam

Ampiroxicam
(CAS: 99464-64-9)

Ampiroxicam is a nonselective cyclooxygenase inhibitor uesd as anti-inflammatory drug.

CAS 15307-86-5 Diclofenac

Diclofenac
(CAS: 15307-86-5)

A non-selective COX inhibitor with IC50 of 60 and 220 nM for ovine COX-1 and -2, respectively.

CAS 633-65-8 Berberine hydrochloride

Berberine hydrochloride
(CAS: 633-65-8)

Berberine hydrochloride is an isoqinoline alkaloid and a COX-2 inhibitor that exhibits chemopreventive activity against colon tumor formation. Study in humans a...

Chemical Structure

CAS 51146-56-6 (S)-(+)-Ibuprofen

Quick Inquiry

Verification code

Featured Items